NVCR News and Press, NovoCure Limited From 06/03/22

Novocure (NASDAQ:NVCR) and Zai Lab (NASDAQ:ZLAB) said a mid-stage study of their investigational device for Tumor Treating Fields (TTFields) met its main goal in patients with gastric cancer. TTFields are electric fields that are believed to disrupt cancer cell division. The co...

Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% Novocure (NASDAQ: NVCR), a global oncology company working to extend surviv...

Confirmed objective response rate was 50% for patients treated with TTFields together with standard-of-care chemotherapy Duration of response was 10.3 months One-year survival was 72% SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass. and ST. HELIER, Jersey, June 03, ...

Novocure (NASDAQ: NVCR) today announced it has entered into a clinical trial collaboration agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, to study the use of Tumor Treating Fields (TTFields) concomitant with MSD’s anti-PD-1 therapy KEYTRUDA ® ...

The spread of the “recession” meme is starting to reach a fever pitch (1). In this case, it could counterintuitively be a positive catalyst for the long duration side of the market – ie, the long-term growth bets that are still in their early innings, with big fireworks s...

H.C. Wainwright has initiated NovoCure (NASDAQ:NVCR) with a buy rating citing international expansion of its core business and four phase 3 studies with readouts expected from 2022-2024. The firm has a $115 price target (~76% upside based on Friday's close). Analyst Emily Bodnar said tha...

PALM BEACH GARDENS, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- AeroClean Technologies (“AeroClean” or the “Company”) (Nasdaq: AERC), a pathogen elimination technology company harnessing patented UV-C LED technology with Pūrgo™ to significantly reduce an...

NovoCure's growth has stalled as their GBM market share has gone to 35%-40%, but GBM still offers several additional growth opportunities. Then there are the 4 P3 trials which, if successful, could add additional cancer treatments and dramatically expand the TAM. That's two years ...

Though there are many companies to choose from, I focus on leading innovators with either novel therapeutics or technologies. NovoCure is a premier developer of tumor treating fields that already enjoyed early market success for glioblastoma multiforme and mesothelioma. As the fir...

Even the best stocks can fall on hard times. That's certainly been the case with plenty of biotech stocks over the past 12 months. However, some that have floundered could still be huge winners over the long term. We asked three Motley Fool contributors to pick beaten-down stocks they t...